Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Cervarix in Women Over 26 Years
NCT00456807Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2007
- Primary completion
- Jan 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection, sponsored by GSK. Started Apr 2007; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00456807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00456807.